5th Floor, Brigade Towers,
Financial District, Gachibowli,
Hyderabad - 500032,
The Protein Engineering Market is segmented by Product Type (Insulin, Monoclonal Antibodies, Coagulation Factors (Blood Factors + Tissue Plasminogen), Vaccines, Growth Factors (Hormones + Cytokine), and Other Product Types), Technology (Irrational Protein Design and Rational Protein Design), End User (Pharmaceutical and Biotechnology Companies, Academic Institutions, and Contract Research Organizations (CROs)), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America).
Fastest Growing Market:
The propelling factors for the growth of the global protein engineering market include the increasing prevalence of protein-deficient diseases, the increase in adoption of protein drugs over non-protein drugs, increased demand for alternatives to chemical processes, and rising government funding for protein engineering.
Protein-energy malnutrition (PEM) is increasing in the rural areas of emerging economies. It refers to a group of disorders that include marasmus, kwashiorkor, and intermediate states of marasmus-kwashiorkor. Therefore, the prevalence of kwashiorkor varies across geographies. It is rare in the United States. However, some of the affected regions include Southeast Asia, Central America, Congo, Puerto Rico, Jamaica, and South Africa. Thus, the increasing prevalence of protein-deficient diseases is driving the demand for the overall market.
There is a rising number of government initiatives, such as funding R&D for protein engineering and awareness programs, which influenced the healthcare industry. Thus, the government is proactively investing in many of the research studies. For instance, Protein Technologies Ltd (PTL) received funding from the UK government’s Technology Strategy Board (now Innovate UK), for its innovative research in protein engineering. Hence, the increasing number of government initiatives for the efficient protein engineering research helps in driving the overall growth of the market.
Protein engineering also holds an immense opportunity in the agrochemical industry, as engineering in proteins may lead to the generation of enzymes with improved function, that may increase the crop yield or facilitate the biofuel production. It is also likely to play an important role as a tool, to attain increased crop yield needed to meet future demands.
As per the scope of the report, protein engineering is the manipulation of the structures of proteins to produce the desired properties, or the synthesis of proteins with particular structures. It is a process by which novel proteins with desired properties are developed, and it has grown enormously since the past three decades. In the past few years, protein engineers have successfully generated a wide range of proteins tailored to specific health, industry, medicine, research, and biotechnology applications.
|By Product Type|
|Coagulation Factors (Blood Factors + Tissue Plasminogen)|
|Growth Factors (Hormones + Cytokine)|
|Other Product Types|
|Irrational Protein Design|
|Rational Protein Design|
|By End User|
|Pharmaceutical and Biotechnology Companies|
|Contract Research Organizations (CROs)|
Report scope can be customized per your requirements. Click here.
Monoclonal antibodies are anticipated to hold the largest market share over the forecast period, owing to their high adoption for numerous therapies, such as cancer and autoimmune diseases. The increasing prevalence of cancer and other autoimmune diseases has significantly increased the use of monoclonal bodies for the treatment of diseases. They also have tremendous applications in the fields of therapeutics, diagnostics, and targeted drug delivery systems, for infectious diseases caused by viruses, bacteria, protozoa, metabolic and hormonal disorders. Hence, recombinant deoxyribonucleic acid technology, through genetic engineering, has successfully led to the possibility of reconstruction of monoclonal antibodies, in turn, fueling the growth of the segment.
To understand key trends, Download Sample Report
Asia-Pacific is expected to witness the fastest CAGR during the forecast period, owing to the growing presence of contract research organizations, rising healthcare IT spending, and unprecedented evolution of the healthcare infrastructure and standards across the region. Growing demand for personalized medicine and strong R&D investments in proteomics-based drug discovery projects are also supplementing the growth of the protein engineering market.
To understand geography trends, Download Sample Report.
The protein engineering market players are highly focused on strategies, such as mergers and acquisitions, new product development initiatives, and geographical expansion. As the cost of R&D is high and requires high-end infrastructure, most of the pharmaceutical and biotechnology companies are moving toward CROs. Most of the players in the CRO industry are joining forces, in order to create a market position.
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Protein-deficient Diseases
4.2.2 Increased Demand for Alternatives to Chemical Processes
4.2.3 Increase in Adoption of Protein Drugs over Non-protein Drugs
4.2.4 Rising Government Funding for Protein Engineering
4.3 Market Restraints
4.3.1 Lack of Experts to Strategize the Process
4.3.2 High Costs
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Product Type
5.1.2 Monoclonal Antibodies
5.1.3 Coagulation Factors (Blood Factors + Tissue Plasminogen)
5.1.5 Growth Factors (Hormones + Cytokine)
5.1.6 Other Product Types
5.2 By Technology
5.2.1 Irrational Protein Design
5.2.2 Rational Protein Design
5.3 By End User
5.3.1 Pharmaceutical and Biotechnology Companies
5.3.2 Academic Institutions
5.3.3 Contract Research Organizations (CROs)
5.4.1 North America
18.104.22.168 United States
22.214.171.124 United Kingdom
126.96.36.199 Rest of Europe
188.8.131.52 South Korea
184.108.40.206 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
220.127.116.11 South Africa
18.104.22.168 Rest of Middle-East and Africa
5.4.5 South America
22.214.171.124 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Agilent Technologies Inc.
6.1.2 Amgen Inc.
6.1.3 Bruker Corporation
6.1.4 Bio-Rad Laboratories Inc.
6.1.5 Eli Lilly and Company
6.1.6 Merck KGaA
6.1.7 Novo Nordisk AS
6.1.8 PerkinElmer Inc.
6.1.9 Thermo Fisher Scientific Inc.
6.1.10 Waters Corporation
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments